Related Experiment Video
Updated: Jun 13, 2026
08:06
Assessment of the Metabolic Effects of Isocaloric 2:1 Intermittent Fasting in Mice
Published on: November 27, 2019
Insights into amylin-leptin synergy
James L Trevaskis1, David G Parkes, Jonathan D Roth
1Amylin Pharmaceuticals, Inc., San Diego, CA 92121, USA.
Trends in Endocrinology and Metabolism: TEM
|April 24, 2010
Summary
Obesity reduces leptin sensitivity, a key energy balance hormone. Amylin may restore leptin responsiveness, offering a new therapeutic strategy for obesity and metabolic disorders.
Area of Science:
- Endocrinology
- Neurobiology
- Metabolic Disorders
Background:
- Leptin is a primary long-term regulator of energy balance.
- Obesity is characterized by resistance to leptin's effects.
- Current strategies to restore leptin sensitivity in obesity are limited.
Purpose of the Study:
- To hypothesize mechanisms by which amylin enhances leptin sensitivity.
- To explore the physiological, neurobiological, and molecular interactions between amylin and leptin.
- To discuss challenges in studying amylin-leptin interactions.
Main Methods:
- Hypothetical review of existing literature on leptin and amylin signaling.
- Analysis of potential physiological and neurobiological pathways.
- Discussion of methodological considerations for future research.
Main Results:
- Amylin agonism is proposed as a potential enhancer of leptin sensitivity.
- Specific physiological and neurobiological mechanisms are hypothesized for amylin-leptin interaction.
- Identification of challenges in translating these findings.
Conclusions:
- Amylin may represent a novel therapeutic target to overcome leptin resistance in obesity.
- Understanding amylin's role in leptin function could lead to broader strategies for metabolic disease.
- Further research is needed to elucidate the precise mechanisms involved.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
01:30Regulation of Food Intake
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:28Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...